Catalog No.
Product Name
Application
Product Information
Citations
-
Dopamine Receptor Inhibitor
SV 293 is a selective antagonist that primarily targets dopamine D2 receptors with a binding affinity that is 100-fold greater than that of D3 and D4 receptor subtypes. This compound exhibits neutral antagonist activity and effectively blocks the effects of the full agonist quinpirole in forskolin-dependent adenylate cyclase inhibition assays and electrophysiological assays. SV 293 serves as a valuable pharmacological tool for investigating the role of D2-like receptor subtypes in dopamine-related pathways associated with neurological, neuropsychiatric, and movement disorders. -
sst2 Receptor Agonist
BIM-23027 is a selective agonist of the sst2 receptor, exhibiting an EC50 of 0.32 nM. This compound mimics the action of somatostatin (SRIF), a cyclic tetradecapeptide, and plays a critical role in stimulating dopamine release through a Glu-dependent mechanism. BIM-23027 is suitable for research applications focusing on neuroendocrine regulation and receptor pharmacology. -
Dopamine Receptor
LY 171859 is a selective D2 receptor agonist that also displays notable reductase activity. This compound demonstrates enzymatic function within the cytoplasm of various tissues, including liver, lung, and kidney, and exhibits significant reductase activity in both rat and human blood. The reduction process mediated by LY 171859 is NADPH-dependent, with an apparent Km of 14.8 μM, and specifically incorporates the A-side hydrogen of NADPH into the reaction product. Additionally, this compound's enzymatic activity is sensitive to inhibition by cyanide and thiol reagents, making it a useful tool for studying dopamine receptor signaling and associated metabolic pathways. -
MOR Agonist
MOR agonist-2 is a potent agonist of the mu-opioid receptor (MOR) with a Ki value of 564 nM, and it acts as an antagonist at the dopamine D3 receptor (D3R) with a Ki of 7.26 nM. This compound exhibits analgesic properties through its partial agonism at MOR, making it a valuable tool for research in pain management. Additionally, its D3R antagonism may help mitigate opioid misuse liability, offering potential therapeutic benefits in addiction studies. -
Antioxidant/Antitumor Agent
Vanicoside E is an antioxidant and antitumor agent that targets L-Tyrosine and L-DOPA, demonstrating inhibitory activity with IC50 values of 45.23 μM and 189.96 μM, respectively. This compound is utilized in research focused on oxidative stress and tumor biology, making it valuable in studies aimed at understanding cancer progression and developing therapeutic strategies. Its properties support investigations into the modulation of key biochemical pathways relevant to tumor growth and survival. -
Dopamine D2 Receptor Antagonist
BRL 34778 is a highly selective dopamine D2 receptor antagonist with a Ki value of 2.14 nM, demonstrating significant potency in receptor inhibition. It exhibits antipsychotic properties while minimizing extrapyramidal side effects and sedation. This compound is valuable for investigating neurological disorders, particularly schizophrenia, and contributes to research focused on the modulation of dopaminergic pathways in the brain. -
Dopamine D1 Receptor Agonist
Zelandopam anhydrous is a selective agonist of the dopamine D1 receptor, exhibiting potent renal vasodilatory effects. This compound demonstrates significant potential in alleviating acute renal failure induced by Cisplatin. It is valuable for research in nephrology and may aid in exploring therapeutic approaches for renal pathologies. -
Dopamine Antagonist
Isoremoxipride is a dopamine antagonist that selectively targets the dopamine D2 receptor. This 3-methoxy isomer demonstrates significant affinity for the receptor, making it a valuable tool for investigating dopamine-related pathways. Its research applications include studies on neuropsychiatric disorders and the role of dopamine in various neurological conditions. -
D4R Antagonist
D4R antagonist-1 is a selective antagonist of the dopamine D4 receptor (D4R) with an IC50 of 6.87 µM. This compound exhibits significant potential for use in research related to neurological disorders, including Parkinson's disease. Its ability to modulate D4R activity makes it a valuable tool for investigating the role of dopamine signaling in various physiological and pathological processes. -
D2R Agonist
rel-Quinpirole dihydrochloride is a selective dopamine D2 receptor agonist that acts primarily on the D2R target. This compound exhibits significant biological activity in modulating dopamine signaling pathways and is utilized in research applications related to neurological diseases, including Parkinson's disease and schizophrenia. Its use can facilitate the investigation of dopaminergic functions and the development of potential therapeutic strategies. -
Dopamine Autoreceptor Antagonist
AJ-76, classified as a dopamine autoreceptor antagonist, plays a crucial role in modulating dopamine levels in the brain. Research shows that AJ-76 enhances the synthesis and turnover of dopamine while exhibiting minimal influence on serotonin and norepinephrine activity. Additionally, AJ-76 effectively counteracts the sedative effects associated with low-dose apomorphine and demonstrates a modest antagonistic effect at postsynaptic dopamine receptors, making it a valuable tool for research in neuropharmacology and the study of dopamine-related disorders. -
Dopamine Agonist
Lergotrile is a potent, orally active dopamine agonist that functions primarily as a prolactin secretion inhibitor. It exerts its biological activity by activating adenohypophyseal dopamine receptors, leading to the inhibition of prolactin release from the pituitary gland. This compound holds potential for research applications related to Parkinson's disease and other dopaminergic disorders. -
Antipsychotic Agent
Piquindone is a potent antipsychotic agent that primarily targets the D2 dopaminergic receptor subtype, exhibiting sodium-dependent binding characteristics. This compound demonstrates significant biological activity relevant to the modulation of dopaminergic signaling and is utilized in research focused on schizophrenia and related neuropsychiatric disorders. -
D3 Receptor Antagonist
Dopamine D3 receptor ligand-6 is a selective antagonist of the dopamine D3 receptor. This compound is valuable for investigating mechanisms involved in substance use disorders, including opioid and psychostimulant addiction. Its specificity for the D3 receptor makes it an important tool in pharmacological studies aimed at understanding and potentially mitigating addiction-related behaviors. -
Dopamine D(3)-Receptor Antagonist
S33084 is a selective antagonist of the dopamine D(3) receptor, exhibiting pKi values of 8.72, 8.62, and 6.82 for cloned rat dopamine D3, native rat dopamine D3, and D2 receptors, respectively. This pharmacological profile indicates its potency and specificity in targeting the D(3) receptor. S33084 is primarily utilized in research focusing on neuropharmacology, aiding investigations into the role of dopamine signaling in various neurological disorders. -
Antidepressant Agent
MeSeI is an antidepressant agent that weakly inhibits monoamine oxidase (MAO) A and B, exhibiting an IC50 value of 198.8 µM. It modulates the activity of dopamine receptor D2 and norepinephrine receptors α2 and β1, demonstrating antidepressant-like effects in animal models. MeSeI is administered orally, making it a convenient candidate for further research into mood disorders and related pharmacological applications. -
Neuroleptic Agent
Fluphenazine decanoate dihydrochloride is a long-acting phenothiazine neuroleptic agent that primarily targets dopamine D2 receptors. It exhibits potent antipsychotic activity, making it valuable for the study of schizophrenia and related disorders. This compound is useful in research aimed at understanding neuropharmacology and the mechanisms underlying psychiatric conditions. -
Dopamine-Blocking Agent
Oxiperomide is an orally active dopamine-blocking agent that primarily targets dopamine receptors. It exhibits significant antagonistic activity, making it useful for studying dopaminergic signaling pathways and related neurophysiological processes. This compound is applicable in research involving neuropsychiatric disorders and the exploration of dopamine's role in various physiological functions. -
Dopamine Uptake Inhibitor
GBR-12879 dihydrochloride is a potent dopamine uptake inhibitor that selectively targets the dopamine transporter. Its primary mechanism involves preventing the reabsorption of dopamine, thus enhancing dopaminergic signaling. This compound is widely utilized in research to investigate the role of dopamine in neurological disorders and to explore potential therapeutic strategies for conditions such as depression and schizophrenia. -
Drug Metabolite
Piribedil N-oxide is a metabolite of the dopamine receptor agonist Piribedil, primarily functioning as a drug metabolite. This compound retains the ability to interact with dopamine receptors, contributing to studies on dopamine signaling pathways and pharmacokinetics. Its characterization is essential for understanding the metabolic fate of Piribedil and its potential implications in neurological research and therapeutic applications. -
Dopamine D4 Receptor Agonist
ABT-724 is a potent and highly selective agonist of the dopamine D4 receptor, exhibiting an EC50 of 12.4 nM for the human receptor. It also demonstrates efficacy as a partial agonist at the rat and ferret D4 receptors, with EC50 values of 14.3 nM and 23.2 nM, respectively. ABT-724 shows minimal activity against dopamine D1, D2, D3, and D5 receptors, making it a valuable tool for exploring the role of the D4 receptor in neurological conditions and potential therapeutic applications for erectile dysfunction. -
Dopamine D2 Receptor Agonist
Quinelorane is a potent dopamine D2 receptor agonist. It has been shown to facilitate semen ejaculation while inhibiting penile erection in rat models. This compound is valuable for investigating mechanisms underlying sexual dysfunction and related therapeutic approaches. -
Stable Isotope
Molindone-d8 is a deuterated form of the antipsychotic agent molindone, primarily used as a stable isotope in scientific research. Its primary mechanism involves dopamine receptor antagonism, reducing the effects of dopamine and helping to mitigate symptoms of schizophrenia. This labeled compound is particularly valuable in pharmacokinetic studies and metabolic research, allowing for precise tracking and analysis of drug behavior in biological systems. -
Stable Isotope
Ropinirole-d3 is a deuterated analog of Ropinirole, primarily targeting D3 and D2 dopamine receptors. As a potent agonist, Ropinirole exhibits a Ki value of 29 nM for the D2 receptor, alongside pEC50 values of 7.4, 8.4, and 6.8 for human D2, D3, and D4 receptors, respectively. This stable isotope is useful in pharmacokinetic studies and can provide insights into the mechanism of action related to dopaminergic therapies, particularly in the context of Parkinson's disease research. -
Bisbenzylisoquinoline Alkaloid Secoderivative
S-Secoantioquine is a bisbenzylisoquinoline alkaloid secoderivative that primarily targets dopamine receptors. It exhibits weak displacement activity on the 3H-SCH 23390 binding site and demonstrates certain displacement activity on the 3H-raclopride binding site in rat striate membrane experiments. This compound is useful for research in neuropharmacology and may aid in understanding the mechanisms of dopaminergic signaling. -
D3 Receptor Agonist
PF 219061 is a selective agonist of the dopamine D3 receptor, exhibiting an EC50 of 15 nM. This compound demonstrates rapid absorption and efficient liver blood clearance, making it suitable for studying female sexual dysfunction. Its specificity for the D3 receptor allows for exploration of its potential therapeutic applications in related disorders. -
Dopamine D4 Receptor Agonist
A-412997 is a selective agonist of the Dopamine D4 receptor, exhibiting Ki values of 12 nM for rat and 7.9 nM for human receptors. This compound has been demonstrated to enhance short-term memory and cognitive functions in rodent models, making it a valuable tool for research into psychiatric disorders and cognitive enhancement. Its specificity and potency facilitate studies on the Dopamine D4 receptor's role in neurobiology and medicine. -
Serotonin-Norepinephrine-Dopamine Releasing Agent
4-Bromoamphetamine hydrochloride is a potent serotonin-norepinephrine-dopamine releasing agent (SNDRA) that exhibits significant stimulant effects. This compound plays a crucial role in neurological research, particularly in studies examining neurotransmitter release and potential neurotoxicity. Notably, 4-Bromoamphetamine hydrochloride has been associated with long-term depletion of serotonin, making it relevant for investigations into neurodegenerative conditions and the mechanisms of neurotransmitter regulation. -
Dopamine Receptor-blocking Agent
(±)-Butaclamol hydrochloride is a dopamine receptor-blocking agent primarily utilized in neuropharmacological research. As the (+)-enantiomer of butaclamol, it demonstrates strong binding affinity to dopamine receptors, making it useful for studying dopamine-mediated pathways. This compound is often applied in the investigation of psychiatric disorders and the development of antipsychotic medications. -
Dopamine D2 Receptor Antagonist
ADR 851 is a potent antagonist of the dopamine D2 receptor, known for its role in neurotransmitter signaling. This compound demonstrates significant activity in modulating dopaminergic pathways and has been utilized in research related to antiemetic therapies. Its effectiveness in targeting the D2 receptor makes it a valuable tool for studies investigating the mechanisms of nausea and emesis. -
Dopamine Receptor Agonist
PD-168077 is a selective agonist for the dopamine D4 receptor, exhibiting a binding affinity (Ki) of 9 nM. This compound demonstrates significant biological activity in modulating dopaminergic signaling pathways, making it a useful tool for research focused on neuropharmacology and psychiatric disorders. Its specificity for the D4 receptor allows for targeted studies in areas such as schizophrenia and addiction, facilitating the exploration of therapeutic interventions. -
Dopamine D1 Receptor Agonist
A-86929 functions as a potent and selective agonist for the dopamine D1 receptor, exhibiting a pKi value of 7.3. It has been shown to significantly induce rotational behavior in the 6-OHDA-induced unilateral nigrostriatal lesion rat model and improve motor function in the MPTP-induced Parkinson's disease marmoset model. Additionally, A-86929 may provide therapeutic insights for reducing cocaine-seeking behavior in rat studies and reversing Haloperidol-induced cognitive deficits in rhesus monkeys. This compound is valuable for research focused on neurological disorders. -
Dopamine Receptor Antagonist
(-)-OSU6162 is a potent presynaptic dopamine receptor antagonist, primarily targeting the D2 dopamine receptor subtype. It exhibits inhibitory effects on dopamine release, making it valuable for research on dopaminergic signaling and its implications in neuropsychiatric disorders. This compound is useful for studying the role of dopamine in various biological systems and can aid in the development of treatments for conditions such as schizophrenia and addiction. -
D4 Receptor Antagonist
PD-89211 is a selective antagonist of the dopamine D4 receptor, exhibiting a Ki value of 3.7 nM. It effectively reverses Quinpirole-induced [3H]thymidine uptake in CHOpro5 cells, with an IC50 of 2.1 nM. This compound plays a significant role in regulating dopamine and norepinephrine metabolism in the hippocampus, making it valuable for research into central nervous system disorders, including schizophrenia. -
Dopaminergic Agonist
GYKI-32887 is a selective dopaminergic agonist that primarily targets dopamine receptors. This compound is notable for its ability to reduce motor activity levels in rodent models, making it a valuable tool for studying dopaminergic signaling pathways and motor function disorders. Its application spans across neuropharmacological research, particularly in understanding the mechanisms of drug action in neurological conditions. -
hD2R Activator
Boc-MIF-1-Am is a potent enhancer of the human dopamine D2 receptor, exhibiting an EC50 value of 17.82 nM. This bioconjugate of melanostatin (MIF-1) and amantadine is primarily utilized in the study of dopaminergic signaling pathways and their implications in neurological disorders. Although Boc-MIF-1-Am demonstrates key biological activity, it has been noted to exhibit mild neurotoxicity at a concentration of 200 μM in SH-SY5Y cells, making careful consideration necessary in experimental designs. -
D2 Receptor Agonist
Sumanirole is a highly selective D2 receptor full agonist, exhibiting an ED50 of approximately 46 nM. This compound is significant in the research of Parkinson's disease and restless leg syndrome, providing insights into dopaminergic signaling pathways. Its potent agonistic activity at the D2 receptor makes it valuable for exploring therapeutic strategies in these neurological disorders. -
Dopamine Receptor Control
Aripiprazole N1-oxide is a metabolite of the atypical antipsychotic drug Aripiprazole, produced through the activity of cytochrome P450 isoforms CYP2D6 and CYP3A4. This compound primarily targets dopamine receptors, influencing dopaminergic signaling pathways. Aripiprazole N1-oxide is significant in research related to psychiatric disorders, enabling the study of receptor modulation and metabolic pathways in drug efficacy and safety. -
D1 Receptor Antagonist
rel-Ecopipam hydrobromide is a potent D1 receptor antagonist with a Ki value of 1.30 nM. This compound effectively inhibits dopamine D1 receptor activity, making it a valuable tool for research in neuropharmacology and the study of dopamine signaling pathways. Its unique mechanism of action positions it for investigations into the role of D1 receptors in various neurobiological processes and potential therapeutic targets for neurological disorders. -
Dopamine Receptors Agonist
Dinoxyline is a potent agonist of dopamine receptors, exhibiting high affinity with Ki values of 7 nM, 6 nM, 5 nM, and 43 nM for D1, D2, D3, and D4 receptors, respectively. This compound is valuable for investigating dopaminergic signaling pathways and their implications in neurological research. Its ability to selectively engage dopamine receptors makes it an essential tool for studies related to mood disorders, addiction, and other neurological conditions. -
DAT/NET/SERT Inhibitor
Amitifadine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that targets the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). It exhibits inhibitory concentrations of 12 nM for serotonin, 23 nM for norepinephrine, and 96 nM for dopamine in HEK 293 cells. This compound is pertinent for research applications exploring the modulation of monoaminergic systems and investigating potential therapeutic effects in mood disorders. -
D2R Antagonist
BRD5814 is a potent antagonist of the dopamine D2 receptor (D2R), a key target in the modulation of dopaminergic signaling. This compound demonstrates significant inhibitory activity, making it a valuable tool in research focused on schizophrenia and other neuropsychiatric disorders. Its application in studies of D2R-related pathways can aid in understanding the complex mechanisms underlying these conditions. -
Dopamine D4 Receptor Partial Agonist
FAUC-312 is a tetrahydropyrimidine that acts as a selective partial agonist of the dopamine D4 receptor, exhibiting a Ki value of 1.5 nM. This compound modulates dopaminergic signaling and has potential applications in researching neuropsychiatric disorders, including schizophrenia and attention deficit hyperactivity disorder (ADHD). Its specificity towards the D4 receptor allows for the exploration of receptor-specific pathways and therapeutic interventions. -
Chlorpromazine Active Metabolite
7-Hydroxychlorpromazine hydrochloride is the active metabolite of Chlorpromazine, primarily targeting dopamine receptors. This compound is known to increase prolactin levels and enhance dopamine turnover, exhibiting notable sedative effects. Research applications include studying psychosis and investigating its efficacy in inhibiting amphetamine-induced stereotyped behaviors in rodent models. -
Dopamine Agonist
PD 118440 is an orally active dopamine agonist that targets dopaminergic signaling pathways within the central nervous system. This compound demonstrates notable biological activity by inhibiting striatal dopamine synthesis and suppressing the firing of dopamine neurons. Additionally, PD 118440 has been shown to reverse Reserpine-induced depression in rodent models, making it a valuable tool for research in neuropharmacology and mood disorder studies. -
Dopamine Agonist
Lergotrile mesylate is a potent orally active dopamine agonist that functions primarily by activating dopamine receptors in the adenohypophysis, thereby inhibiting prolactin secretion. This mechanism contributes to its potential applications in the research of Parkinson's disease and related disorders. By modulating dopamine activity, Lergotrile mesylate serves as a valuable tool for exploring therapeutics targeting dopaminergic pathways. -
Dopamine Receptor Agonist
Disulergine is an ergot alkaloid that acts as a dopamine receptor agonist. It has been shown to inhibit prolactin secretion in rats and also suppress the release of growth hormone (GH). This compound is particularly relevant for research applications exploring the regulation of hormonal pathways and the physiological effects of dopamine receptor modulation. -
Central Dopamine Receptor Antagonist
Brl 20596 is a potent central dopamine receptor antagonist. This compound exhibits significant inhibitory activity at dopamine receptors, making it valuable for antipsychotic research. Its ability to modulate dopaminergic signaling can aid in the investigation of neuropsychiatric disorders related to dopamine dysregulation. -
DA2 Receptor Agonist
7-Hydroxy ropinirole bromide is a selective DA2 receptor agonist that demonstrates significant inhibitory effects on neurotransmitter release and sympathetic nerve responses. This compound, a derivative of N,N-di-n-propyldopamine (DPDA), has shown promise in isolated perfused rabbit ear artery models, making it a valuable tool for studying cardiovascular and neurological disorders. Its targeted mechanism of action underscores its relevance in exploring therapeutic interventions in these fields. -
CI-1007 Active Metabolite
PD-147693 is the active metabolite of the presynaptic dopamine autoreceptor agonist CI-1007, exhibiting antipsychotic activity akin to its parent compound. This reagent is utilized in neuropharmacological research to explore the mechanisms of dopaminergic signaling and evaluate potential therapeutic approaches for neuropsychiatric disorders. Its relevance extends to studies focused on dopamine receptor interactions and their implications in psychopharmacology.
